Anti-virus agent 2 

Anti-virus agent 2 is an orally active and selective anti-orthopoxvirus (poxvirus) agent, with EC₅₀ values of 6.1 μM and 47.1 μM against VTT-Fluc and MPXV clade IIb, respectively. Anti-virus agent 2 covalently binds to viral A17L protein and mRNA methyltransferase, blocks viral membrane fusion and intracellular biosynthesis, and acts on multiple stages of the viral replication cycle. Anti-virus agent 2 achieves viral inhibition in nude mouse models. Anti-virus agent 2 can be used for the research of orthopoxvirus infections such as monkeypox and smallpox^[1].

Anti-virus agent 2 (compound 8l) potently inhibits VTT-Fluc replication in Vero cells with an EC₅₀ of 6.1 μM and a selective index of 64.7, and moderately inhibits MPXV clade IIb replication in Vero cells with an EC₅₀ of 47.1 μM^[1].
Anti-virus agent 2 (5-25 μM; 1 h at specified time points, followed by 23 h culture) interferes with viral membrane fusion and intracellular biosynthesis stages of VTT-Fluc replication in Vero cells when administered 1 hour postinfection^[1].
Anti-virus agent 2 (60 s association, 60 s dissociation) binds specifically to viral cap-specific mRNA methyltransferase with a K_D of 7.64 μM^[1].
Anti-virus agent 2 (40 μM; 2 h, then heated at 37-73 °C for 4 min) enhances the thermal stability of viral cap-specific mRNA methyltransferase, confirming a high-affinity interaction^[1].
Anti-virus agent 2 binds specifically to viral A17L protein with a K_D of 7.28 μM, and binds weakly to human cap methyltransferase 2 with a K_D of 491 μM, demonstrating selectivity for viral MTase over the human homolog^[1].
Anti-virus agent 2 (6.25-100 μM; 24 h) has low cytotoxicity in human A549, H460, and CX-1 cell lines, with CC₅₀ values greater than 100 μM^[1].
Anti-virus agent 2 forms a covalent Michael addition adduct with L-serine, and covalently modifies Ser155 of viral cap-specific mRNA methyltransferase and Ser140 of viral A17L protein via Michael addition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-virus agent 2 (compound 8l) (45, 90 mg/kg; p.o.; once daily; 5 days) achieves viral inhibition rates of 87.4% and 88.2%, respectively, and protects against vaccinia virus-induced tissue damage in nude mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

311.33

C₁₈H₁₇NO₄

OC(C1=C(NC(/C=C/CC2=CC=C(OC)C=C2)=O)C=CC=C1)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ni Y, et al. Structural Modification of Tranilast against Poxvirus Based on α, β-Unsaturated Acrylamide Covalent Warhead and Confirmation of the Targets and Mode of Action. J Med Chem. Published online April 30, 2026.